Cargando…

Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury

Cisplatin (CDDP) is a widely used anticancer drug, but acute kidney injury (AKI) is one of the most important dose-limiting factors. Trace metal elements are present in various concentrations in the body and play an important role in maintaining normal vital functions. However, the relationship betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Yuko, Hotta, Yuji, Tomita, Natsumi, Naiki-Ito, Aya, Kitagawa, Ayae, Kuboshiki, Urara, Hagita, Tamaki, Noda, Misuzu, Sanagawa, Akimasa, Kataoka, Tomoya, Kondo, Masahiro, Furukawa-Hibi, Yoko, Takahashi, Satoru, Kimura, Kazunori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860105/
https://www.ncbi.nlm.nih.gov/pubmed/36691436
http://dx.doi.org/10.1016/j.bbrep.2023.101422
_version_ 1784874503036207104
author Yamamoto, Yuko
Hotta, Yuji
Tomita, Natsumi
Naiki-Ito, Aya
Kitagawa, Ayae
Kuboshiki, Urara
Hagita, Tamaki
Noda, Misuzu
Sanagawa, Akimasa
Kataoka, Tomoya
Kondo, Masahiro
Furukawa-Hibi, Yoko
Takahashi, Satoru
Kimura, Kazunori
author_facet Yamamoto, Yuko
Hotta, Yuji
Tomita, Natsumi
Naiki-Ito, Aya
Kitagawa, Ayae
Kuboshiki, Urara
Hagita, Tamaki
Noda, Misuzu
Sanagawa, Akimasa
Kataoka, Tomoya
Kondo, Masahiro
Furukawa-Hibi, Yoko
Takahashi, Satoru
Kimura, Kazunori
author_sort Yamamoto, Yuko
collection PubMed
description Cisplatin (CDDP) is a widely used anticancer drug, but acute kidney injury (AKI) is one of the most important dose-limiting factors. Trace metal elements are present in various concentrations in the body and play an important role in maintaining normal vital functions. However, the relationship between CDDP-induced AKI and trace metal elements is unknown. In this study, we cultured human renal proximal tubular epithelial cells in the presence of CDDP (0, 12.5, 25, 50 μM) and analyzed the concentration of trace elements in medium after 24 h. We found that CDDP significantly increased the concentrations of zinc (Zn) and manganese (Mn) in medium and significantly decreased them in lysate. Therefore, we examined the effects of CDDP (3 mg/kg, i.p.) administration on serum and urinary Zn and Mn concentrations in rats. The results showed that urinary excretion of Zn and Mn increased in CDDP-treated rats 5 days after administration. Also, 5 days after administration, pyknosis, nuclear loss, loss of the brush border membrane, and DNA fragmentation were observed, and serum creatinine and blood urea nitrogen levels were found to be significantly increased. These data suggested that 24-h excretion of Zn and Mn might reflect on CDDP induced nephropathy. Monitoring urinary Zn and Mn excretion may be beneficial in detecting AKI, but further studies are needed for clinical application.
format Online
Article
Text
id pubmed-9860105
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-98601052023-01-22 Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury Yamamoto, Yuko Hotta, Yuji Tomita, Natsumi Naiki-Ito, Aya Kitagawa, Ayae Kuboshiki, Urara Hagita, Tamaki Noda, Misuzu Sanagawa, Akimasa Kataoka, Tomoya Kondo, Masahiro Furukawa-Hibi, Yoko Takahashi, Satoru Kimura, Kazunori Biochem Biophys Rep Research Article Cisplatin (CDDP) is a widely used anticancer drug, but acute kidney injury (AKI) is one of the most important dose-limiting factors. Trace metal elements are present in various concentrations in the body and play an important role in maintaining normal vital functions. However, the relationship between CDDP-induced AKI and trace metal elements is unknown. In this study, we cultured human renal proximal tubular epithelial cells in the presence of CDDP (0, 12.5, 25, 50 μM) and analyzed the concentration of trace elements in medium after 24 h. We found that CDDP significantly increased the concentrations of zinc (Zn) and manganese (Mn) in medium and significantly decreased them in lysate. Therefore, we examined the effects of CDDP (3 mg/kg, i.p.) administration on serum and urinary Zn and Mn concentrations in rats. The results showed that urinary excretion of Zn and Mn increased in CDDP-treated rats 5 days after administration. Also, 5 days after administration, pyknosis, nuclear loss, loss of the brush border membrane, and DNA fragmentation were observed, and serum creatinine and blood urea nitrogen levels were found to be significantly increased. These data suggested that 24-h excretion of Zn and Mn might reflect on CDDP induced nephropathy. Monitoring urinary Zn and Mn excretion may be beneficial in detecting AKI, but further studies are needed for clinical application. Elsevier 2023-01-13 /pmc/articles/PMC9860105/ /pubmed/36691436 http://dx.doi.org/10.1016/j.bbrep.2023.101422 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Yamamoto, Yuko
Hotta, Yuji
Tomita, Natsumi
Naiki-Ito, Aya
Kitagawa, Ayae
Kuboshiki, Urara
Hagita, Tamaki
Noda, Misuzu
Sanagawa, Akimasa
Kataoka, Tomoya
Kondo, Masahiro
Furukawa-Hibi, Yoko
Takahashi, Satoru
Kimura, Kazunori
Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury
title Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury
title_full Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury
title_fullStr Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury
title_full_unstemmed Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury
title_short Changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury
title_sort changes in zinc and manganese concentrations in cisplatin-induced acute kidney injury
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860105/
https://www.ncbi.nlm.nih.gov/pubmed/36691436
http://dx.doi.org/10.1016/j.bbrep.2023.101422
work_keys_str_mv AT yamamotoyuko changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury
AT hottayuji changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury
AT tomitanatsumi changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury
AT naikiitoaya changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury
AT kitagawaayae changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury
AT kuboshikiurara changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury
AT hagitatamaki changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury
AT nodamisuzu changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury
AT sanagawaakimasa changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury
AT kataokatomoya changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury
AT kondomasahiro changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury
AT furukawahibiyoko changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury
AT takahashisatoru changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury
AT kimurakazunori changesinzincandmanganeseconcentrationsincisplatininducedacutekidneyinjury